Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9573 posts found.

GSK drops herpes vaccine

October 4, 2010 Research and Development, Sales and Marketing GlaxoSmithKline, Simplirix, herpes, sexual health

Poor phase III results have forced GlaxoSmithKline to halt development of its Simplirix vaccine for women with genital herpes. The …
News

Talking R&D: US regulatory guidelines

October 4, 2010 Manufacturing and Production, Research and Development Talking R&D, eCTD submissions

Recent speculation surrounding current diabetes drugs and their long term effect on cardiovascular health has heads spinning in the pharmaceutical …
Feature

AZ-BMS diabetes drug impresses in phase III trials

October 1, 2010 Research and Development, Sales and Marketing AstraZeneca, BMS, dapagliflozin, diabetes

AstraZeneca and Bristol Myers Squibb’s potential first-in-class diabetes drug dapagliflozin has shown strong results in a late stage trial. It …
News

FDA unveils new trial data rules

October 1, 2010 Research and Development FDA, clinical trials, pharmacovigilance

The FDA has clarified its rules on what safety information must be reported during clinical trials of investigational drugs and …
News

BMS poaches AZ’s head of global medical affairs

October 1, 2010 Research and Development, Sales and Marketing BMS, appointment, research and development, sales and marketing

Bristol-Myers Squibb has appointed Dr Rick Lones as executive medical director in the UK. He joins BMS from AstraZeneca, where …
Appointment

Sanofi signs $2.2bn CRO deal

October 1, 2010 Research and Development CRO, Covance, Sanofi-Aventis

Sanofi-Aventis has signed a major deal to contract out a wide range of drug development and laboratory services as part …
News
FDA director of manufacturing and product quality Rich Friedman

The FDA Interview: Is pharma getting worse at manufacturing?

September 29, 2010 Manufacturing and Production, Research and Development FDA, manufacturing, manufacturing compliance

It seems that barely a week goes by at the moment without news of another pharmaceutical company falling foul of …
Feature

Contract research news in brief

September 29, 2010 Research and Development CIT, Cardialysis, PPD, Parexel, Porsolt, Sticares

A round-up of recent news from the CRO sector, featuring updates from CIT, Parexel, PPD, Cardialysis/Sticares and Porsolt. French non-clinical …
News

ClinTec recruits former Wyeth VP

September 29, 2010 Research and Development ClinTec, appointment, research and development

Glasgow, UK-based contract research organisation ClinTec has expanded its US operations with the appointment of new executive vice president Dr …
Appointment

Pfizer slims down pipeline

September 28, 2010 Research and Development Pfizer

Pfizer has reduced the number of drugs in its product pipeline as part of a broad refocusing of its R&D …
News

European Commission eyes pharma ethics

September 27, 2010 Research and Development, Sales and Marketing European Commission, corporate responsibility, ethics

The European Commission is to examine corporate responsibility in the pharmaceutical industry with the aim of developing a series of …
News

Dr Alan Palmer joins One Nucleus

September 27, 2010 Research and Development One Nucleus, apppointment, research and development

Cambridge, UK-based life sciences body One Nucleus has appointed Dr Alan Palmer as a director. Alan is co-founder and chief …
Appointment

Gene-targeting asthma drugs within a decade

September 24, 2010 Research and Development asthma, genetic

Asthma treatments that target genetic variants found in people susceptible to the condition could be available within the next ten …
News

Solid results for AstraZeneca’s oral RA drug

September 23, 2010 Research and Development AstraZeneca, Rigel, fostamatinib, rheumatoid arthritis

AstraZeneca’s new oral treatment for rheumatoid arthritis has produced solid results in a phase II trial. Fostamatinib is the first …
News

Gilenya approved as new frontline MS treatment

September 22, 2010 Research and Development, Sales and Marketing Cladribine, FDA, Novartis, gilenya

Novartis’ new multiple sclerosis treatment Gilenya has been approved by the FDA, and is set to significantly alter the way …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025